Anna Karina Juhl

Anna Karina Juhl

Auto-generated profile, based on publicly available information

Anna Karina Juhl

Department of Clinical Medicine, Aarhus University , Aarhus

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in Communications Medicine
Verified
Journal Article
Open access
PDF file
LDLisa Loksø Dietz
Lisa Loksø Dietz
AJAnna Karina Juhl
Anna Karina Juhl
OSOle S. Søgaard
Ole S. Søgaard
JRJoanne Reekie
Joanne Reekie
HNHenrik Nielsen
Henrik Nielsen
MTMartin Tolstrup
Martin Tolstrup
Background: Older age and chronic disease are important risk factors for developing severe COVID-19. At population level, vaccine-induced immunity substantially reduces the risk of severe COVID-19 disease and hospitalization. However, the relative impact of humoral and cellular immunity on protection from breakthrough infection and severe disease is not fully understood. Methods: In a study cohort of 655 primarily older study participants (median of 63 years (IQR: 51–72)), we determined serum levels of Spike IgG antibodies using a Multiantigen Serological Assay and quantified the frequency of SARS-CoV-2 Spike-specific CD4 + and CD8 + T cells using activation induced marker assay. This enabled characterization of suboptimal vaccine-induced cellular immunity. The risk factors of being a cellular hypo responder were assessed using logistic regression. Further follow-up of study participants allowed for an evaluation of the impact of T cell immunity on breakthrough infections. Results: We show reduced serological immunity and frequency of CD4 + Spike-specific T cells in the oldest age group (≥75 years) and higher Charlson Comorbidity Index (CCI) categories. Male sex, age group ≥75 years, and CCI > 0 is associated with an increased likelihood of being a cellular hypo-responder while vaccine type is a significant risk factor. Assessing breakthrough infections, no protective effect of T cell immunity is identified. Conclusions: SARS-CoV-2 Spike-specific immune responses in both the cellular and serological compartment of the adaptive immune system increase with each vaccine dose and are progressively lower with older age and higher prevalence of comorbidities. The findings contribute to the understanding of the vaccine response in individuals with increased risk of severe COVID-19 disease and hospitalization.

10 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
FRFrederik Holm Rothemejer
Frederik Holm Rothemejer
NLNanna Pi Lauritsen
Nanna Pi Lauritsen
AJAnna Karina Juhl
Anna Karina Juhl
MSMariane Høgsbjerg Schleimann
Mariane Høgsbjerg Schleimann
SKSaskia König
Saskia König
MTMartin Tolstrup
Martin Tolstrup
Adoptive immunotherapy using chimeric antigen receptor (CAR) T cells has been highly successful in treating B cell malignancies and holds great potential as a curative strategy for HIV infection. Recent advances in the use of anti-HIV broadly neutralizing antibodies (bNAbs) have provided vital information for optimal antigen targeting of CAR T cells. However, CD4+ CAR T cells are susceptible to HIV infection, limiting their therapeutic potential. In the current study, we engineered HIV-resistant CAR T cells using CRISPR/Cas9-mediated integration of a CAR cassette into the CCR5 locus. We used a single chain variable fragment (scFv) of the clinically potent bNAb 10-1074 as the antigen-targeting domain in our anti-HIV CAR T cells. Our anti-HIV CAR T cells showed specific lysis of HIV-infected cells in vitro. In a PBMC humanized mouse model of HIV infection, the anti-HIV CAR T cells expanded and transiently limited HIV infection. In conclusion, this study provides proof-of-concept for developing HIV-resistant CAR T cells using CRISPR/Cas9 targeted integration.

30 April 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AJAnna Karina Juhl
Anna Karina Juhl
LDLisa Loksø Dietz
Lisa Loksø Dietz
OSOle Schmeltz Søgaard
Ole Schmeltz Søgaard
JRJoanne Reekie
Joanne Reekie
HNHenrik Nielsen
Henrik Nielsen
MTMartin Tolstrup
Martin Tolstrup
Within a year of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, vaccines inducing a robust humoral and cellular immune response were implemented worldwide. However, emergence of novel variants and waning vaccine-induced immunity led to implementation of additional vaccine boosters. This prospective study evaluated the temporal profile of cellular and serological responses in a cohort of 639 SARS-CoV-2–vaccinated participants, of whom a large proportion experienced a SARS-CoV-2 infection. All participants were infection naïve at the time of their first vaccine dose. Proportions of SARS-CoV-2 spike–specific T cells were determined after each vaccine dose using the activation-induced marker assay, while levels of circulating SARS-CoV-2 antibodies were determined by the Meso Scale serology assay. We found a significant increase in SARS-CoV-2 spike–specific CD4+ and CD8+ T-cell responses following the third dose of a SARS-CoV-2 messenger RNA vaccine as well as enhanced CD8+ T-cell responses after the fourth dose. Furthermore, increased age was associated with a poorer response. Finally, we observed that SARS-CoV-2 infection boosts both the cellular and humoral immune response, relative to vaccine-induced immunity alone. Our findings highlight the boosting effect on T-cell immunity of repeated vaccine administration. The combination of multiple vaccine doses and SARS-CoV-2 infections maintains population T-cell immunity, although with reduced levels in the elderly. This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/longitudinal-evaluation-of-sars-cov-2-t-cell-immunity-over-2-years-following-vaccination-and-infection?utm_campaign=tidbitlinkshare&utm_source=ITP

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
NSNina Breinholt Stærke
Nina Breinholt Stærke
JRJoanne Reekie
Joanne Reekie
HNHenrik Nielsen
Henrik Nielsen
TBThomas Benfield
Thomas Benfield
LWLothar Wiese
Lothar Wiese
OSOle S. Søgaard
Ole S. Søgaard
Background: Vaccines based on the Wuhan strain of SARS-CoV-2 are a cornerstone of the global management of the COVID-19 pandemic. However, variants of concern have continuously evolved and may erode previously induced immunity. This study aimed to determine risk of breakthrough infection in a fully vaccinated cohort. Methods: Participants were enrolled before their first SARS-CoV-2 vaccination and SARS-CoV-2 anti-spike IgG levels were measured after 21–28, 90 and 180 days of follow-up, as well as day -7 and 28 after booster vaccination. Rate of breakthrough infections were ascertained from two weeks after the second vaccine dose, and captured through the Danish National Microbiology database. Poisson regression analysis was used to determine the risk of breakthrough infection at time-updated anti-spike IgG levels after adjustment for age, sex, being health care worker, and time-updated SARS-CoV-2 transmission level. Findings: Among 6076 participants (median age 64 years, interquartile range 55–75) included in this analysis, breakthrough infections due to the Delta variant were observed in 127 participants and in 363 due to the Omicron variant. The incidence rate ratio (IRR) for breakthrough infection with the Delta variant decreased with higher levels of anti-spike IgG yielding an IRR of 0.28 (95% CI 0·15–0·55) when comparing the highest and lowest quintiles of anti-spike IgG. For the Omicron variant, no significant differences in IRR of breakthrough infection between quintiles of anti-spike IgG was observed. Notably, 1 of 127 (0·8%) SARS-CoV-2 Delta variant and 0 of 336 (0%) Omicron variant breakthrough infections resulted in severe COVID-19. Interpretation: We observed a strong association between increasing levels of anti-spike antibodies and reduced risk of breakthrough infections with the Delta but not the Omicron variant. However, despite a high proportion of elderly participants, severe COVID-19 was rare in both Delta and Omicron infections. Trial Registration Details: The study was approved by the Danish Medicines Agency (Eudra CT number:2020-006003-42). Funding Information: This study was fully funded by the Danish Ministry of Health (act 150, January 28th 2021). Declaration of Interests: HN declares participation on advisory board meeting with GSK and MSD. TB declares receipt of unrestricted research or travel grants from GSK, Pfizer, Gilead Sciences, MSD; and being principal investigator on trials conducted by Boehringer Ingelheim, Roche, Novartis, Kancera, Pfizer, MSD and Gilead; Board member on Pentabase, and advisory board member for MSD, Gilead, Pfizer, GSK, Janssen and AstraZeneca; consulting fees from GSK and Pfizer; receiving donation of study drug from Eli Lilly; and receiving honorarium for lectures from GSK, Pfizer, Gilead Sciences, Boehringer Ingelheim, Abbvie and AstraZeneca. NS declares being principal investigator on studies conducted by Pfizer and Gilead. All other authors declare no conflicts of interest. Ethics Approval Statement: The study was approved by the Ethics Committee of the Central Denmark Region (#1-10-72-337-20). All participants received written and oral information about the study before providing their consent to participate.

2 September 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
AAAnders B Andersen
Anders B Andersen
AJAnna K Juhl
Anna K Juhl
JGJesper Gunst
Jesper Gunst
TRThomas A Rasmussen
Thomas A Rasmussen
MTMartin Tolstrup
Martin Tolstrup
OSOle S Søgaard
Ole S Søgaard
Background: CD8+ T-cell responses are thought to be critical for spontaneous control of human immunodeficiency virus type 1 (HIV), but findings supporting their role in postintervention control have been mixed. We hypothesized that HIV-specific T-cell proliferation, interferon-gamma (IFN-γ), and granzyme B responses prior to analytical treatment interruption (ATI) were associated with time to viral rebound. Methods: We pooled data from 6 different HIV cure trials including people with HIV receiving antiretroviral therapy (ART) alone or combined with latency-reversing agents, Toll-like receptor 9 agonists, or broadly neutralizing antibodies. Pre-ATI blood samples were analyzed by IFN-γ enzyme-linked immunosorbent spot (ELISpot) assay and lymphocyte proliferation assay (LPA). Results: We included 91 participants (90% male, median age 45 years). Compared to participants without virologic control (2 consecutive HIV RNA measurements >1000 copies/mL or ART restart), participants with virologic control at day 28 post-ATI (n = 49) had higher Gag-specific IFN-γ (210 vs 50 spot-forming units/106 peripheral blood mononuclear cells, P = .03) and CD8+ T-cell proliferation (0.48% vs 0.16%, P = .03) responses pre-ATI. The median duration of virologic control was 28 versus 21 days in people with high versus low Gag-specific IFN-γ response (P < .01) or CD8+ T-cell proliferation (P = .03). ELISpot and LPA responses were not associated with time to first plasma HIV RNA of >50 copies/mL. Conclusions: These findings indicate that high pre-ATI Gag-specific IFN-γ and CD8+ T-cell proliferation responses were associated with an increase in the duration of virological control after stopping ART, supporting a role for CD8+ T cells in sustaining virological control.